Alanine Aminotransferase news

All news on Alanine Aminotransferase (also known as ALT, GPT, and Glutamate Pyruvate Transaminase): plants, production capacities, investments and involved companies.

7 June 2026

Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
10 November 2025

Novo Nordisk: Wegovy® Shows Liver Health Benefits Beyond Weight Loss in MASH Patients

Semaglutide 2.4 mg improves liver health in MASH patients, showing benefits across weight loss levels and diverse demographics, according to ESSENCE trial data.

Who will be producing Alanine Aminotransferase in the future?

Find out with chemXplore Alpha

Learn more